PACTR202206666476182Other1 期
Phase 1 Open Label, Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Intradermal Booster Dose of INO-4800 Alone or in Combination With INO-9112 Followed by Electroporation, in Adults Who Completed a Primary Immunization Series Against SARS-CoV-2 With mRNA Vaccines
Inovio Pharmaceuticals Inc.0 个研究点目标入组 160 人开始时间: 2022年6月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- Other
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 13 Year(s) 至 18 Year(s)（—）
- 性别
- All
入选标准
- •Healthy men and non-pregnant women at least 18 years of age;
- •Able and willing to comply with all study procedures;
- •Screening laboratory results within normal limits or deemed not clinically significant by the Investigator;
- •Received full primary series doses of an approved or authorized mRNA vaccine at least 6 months but no more than 12 months prior to INO-4800 booster dose.
- •Must meet one of the following criteria with respect to reproductive capacity:
- •Women who are post-menopausal as defined by reported spontaneous amenorrhea for = 12 months;
- •Surgically sterile (i.e., vasectomy in males or tubal ligation, absence of ovaries and/or uterus in females). In the case of vasectomy, participants should wait six (6) months post-vasectomy prior to enrollment;
- •Use of medically effective contraception with a failure rate of < 1% per year when used consistently and correctly from screening until Day 28 post booster dose.
排除标准
- •Acute febrile illness with temperature >100.4°F (38.0°C) or acute onset of upper or lower respiratory tract symptoms (e.g., cough, shortness of breath, sore throat) within the prior 72 hours;
- •Positive SARs-CoV-2 PCR test, if results are available prior to dosing;
- •Pregnant or breastfeeding, or intending to become pregnant or intending to father children within the projected duration of the study starting from the Screening visit until Day 28 post booster dose;
- •Positive pregnancy test during screening or immediately prior to booster dose;
- •Positive HIV rapid test, Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody at Screening;
- •Is currently participating or has participated in a study with an IP within 30 days preceding Day 0 (documented receipt of placebo in a previous study would be permissible for study eligibility);
- •Currently participating in another study with an investigational product during the conduct of this study;
- •Previous or planned receipt of any COVID-19 booster vaccine during the trial period
- •Medical conditions as follows:
- •Respiratory diseases
- •History of hypersensitivity or severe allergic reaction
- •Uncontrolled hypertension
- •Uncontrolled diabetes mellitus
- •Malignancy within the past 2 years, with the exception of superficial skin
- •History of cardiovascular
- •History of seizures within the past 2 years
- •Underlying immunosuppressive illness
- •Lack of acceptable sites for ID injection and EP
- •Blood donation or transfusion within 1 month prior to Day 0;
- •Reported alcohol or substance abuse/dependence or illicit drug use within the past year;
- •Any non-study vaccine (e.g., influenza vaccine) within 2 weeks prior to the dose of IP.
研究者
相似试验
已完成
1 期
A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy VolunteersStem cell mobilisationBlood - Haematological diseasesACTRN12614000200684Antisense Therapeutics10
进行中（未招募）
1 期
A Study Evaluating Ramucirumab in Children and Young Adults with Synovial Sarcoma.MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Synovial SarcomaEUCTR2018-004243-23-ESilly S.A.23
进行中（未招募）
1 期
A Study Evaluating Ramucirumab in Children and Young Adults with Synovial Sarcoma.Synovial SarcomaEUCTR2018-004243-23-NLEli Lilly and Company34
进行中（未招募）
1 期
A Study Evaluating Ramucirumab in Children and Young Adults with Synovial Sarcoma.Synovial SarcomaEUCTR2018-004243-23-BEEli Lilly and Company30
进行中（未招募）
1 期
A Study Evaluating Ramucirumab in Children and Young Adults with Synovial Sarcoma.Synovial SarcomaMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004243-23-DEEli Lilly and Company34